BioVie Inc. (NASDAQ:BIVIW – Get Free Report) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 50,400 shares, a growth of 67.7% from the October 15th total of 30,050 shares. Based on an average trading volume of 22,475 shares, the days-to-cover ratio is currently 2.2 days.
BioVie Stock Performance
Shares of BIVIW stock opened at $0.29 on Monday. The business’s 50 day moving average is $0.30 and its two-hundred day moving average is $0.32. BioVie has a twelve month low of $0.13 and a twelve month high of $0.79.
BioVie Inc. is a clinical-stage biopharmaceutical company developing treatments for liver and neurological disorders. Its research includes therapies for conditions associated with inflammation and impaired organ function. The company’s development programs include BIV201, an investigational continuous-infusion formulation of terlipressin being studied for ascites associated with cirrhosis, and NE3107, an investigational oral drug candidate being studied for neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.
See Also
- Five stocks we like better than BioVie
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
